Web-Banner-for-LNC.jpg

New Drug Indications - November 2022


durvalumab

Imfinzi

Pharmaceutical company: AstraZeneca

NEW INDICATION & DOSAGE

Metastatic or locally advanced biliary tract cancer in combination with gemcitabine and cisplatin

Adults weighing 30 kg or more: 1,500-mg IV infusion every 3 weeks (21 days) for up to eight cycles in combination with chemotherapy, followed by 1,500 mg every 4 weeks as a single agent until disease progression or unacceptable toxicity occurs.

Adults weighing less than 30 kg: 20-mg/kg IV infusion every 3 weeks (21 days) for up to eight cycles in combination with chemotherapy, followed by 20 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity occurs.

Released: November 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


lumacaftor and ivacaftor

Orkambi

Pharmaceutical company: Vertex Pharmaceuticals

NEW AVAILABLE FORM

Oral granules (single-dose packets):lumacaftor 150 mg and ivacaftor 188 mg; lumacaftor 100 mg and ivacaftor 125 mg; lumacaftor 75 mg and ivacaftor 94 mg

INDICATION & DOSAGE

Treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene

Children ages 1 to 2 and weighing 14 kg or greater: 1 granule packet (lumacaftor 150 mg and ivacaftor 188 mg) every 12 hours with fat-containing food.

Children ages 1 to 2 and weighing 9 to less than 14 kg: 1 granule packet (lumacaftor 100 mg and ivacaftor 125 mg) every 12 hours with fat-containing food.

Children ages 1 to 2 and weighing 7 to less than 9 kg: 1 granule packet (lumacaftor 75 mg and ivacaftor 94 mg) every 12 hours with fat-containing food.

Released: November 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer